The lancet oncology
-
The lancet oncology · Mar 2007
Meta Analysis Comparative StudySurvival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
Resectable oesophageal cancer is often treated with surgery alone or with preoperative (neoadjuvant) chemoradiotherapy or chemotherapy. We aimed to clarify the benefits of neoadjuvant chemoradiotherapy or chemotherapy versus surgery alone by a meta-analysis of randomised trial data. ⋯ A significant survival benefit was evident for preoperative chemoradiotherapy and, to a lesser extent, for chemotherapy in patients with adenocarcinoma of the oesophagus. The findings provide an evidence-based framework for the use of neoadjuvant treatment in management decisions.
-
The lancet oncology · Mar 2007
Biography Historical ArticleWilliam Stewart Halsted: his life and contributions to surgery.
William Stewart Halsted was a pioneer of surgery in the USA and made many wide-ranging contributions, including the surgical treatment of breast cancer. He changed the training of surgeons from a disorganised apprenticeship to the residency training programmes used today. ⋯ Over a 40-year career, beginning in New York and continuing at Johns Hopkins University Hospital in Baltimore, he endured a terrible struggle resulting from an accidental addiction, acquired in the course of his research. Despite this, his legacy to medicine and human health is one of the greatest left by any individual surgeon in history and remains an inspiration today.
-
The lancet oncology · Mar 2007
Randomized Controlled Trial Multicenter Study Comparative StudyGemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
We aimed to compare the additional benefit of gemcitabine when combined with vinorelbine above that of standard vinorelbine treatment in patients with metastatic breast cancer. ⋯ Patients with metastatic breast cancer assigned gemcitabine and vinorelbine had better progression-free survival compared with those assigned vinorelbine alone. However, this finding did not translate into a difference in overall survival. Although toxicity was manageable, patients in the combined group had more haematological toxic effects. These factors should be taken into account when deciding which chemotherapy patients should receive.